Discover how ROE, P/B ratios, and other key metrics can help you value insurance companies for better investment decisions.
MetLife, Inc. (MET) Presents at Bank of America Financial Services Conference 2026 Transcript
MetLife is rated a 'hold' due to modest upside, stable dividend, and shares trading slightly below fair value. MET's 'New Frontier' restructuring targets 10% EPS growth, 15-17% ROE, and an 11.3% expense ratio by 2029, with progress evident. The PineBridge acquisition scales global asset management and diversifies revenue, but limited near-term financial impact is expected.
MetLife, Inc. (MET) Q4 2025 Earnings Call Prepared Remarks Transcript
MET's Q4 adjusted EPS beat estimates as higher volumes lifted Asia, Group Benefits, RIS and EMEA, offset partly by a Mexico VAT hit.
MetLife, Inc. (MET) Q4 2025 Earnings Call Transcript
The headline numbers for MetLife (MET) give insight into how the company performed in the quarter ended December 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
MET prepares to report Q4 results, with earnings and revenues expected to rise, driven by premium growth and stronger international operations.
Evaluate the expected performance of MetLife (MET) for the quarter ended December 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
MET may be worth retaining as higher premiums, cost cuts, strong liquidity and a low forward P/E support growth despite its recent underperformance.
MET is embedding pet insurance into shelter adoptions via Petstablished, letting adopters bundle coverage into fees and protect pets from day one.
BRK.B and MET remain resilient amid rate cuts and rising climate risks, but one outpaces the other in terms of ROE and growth.